4007-79-8

Usage

Uses

Used in Pharmaceutical Industry:
5,5-Dimethylpiperidin-2-one is used as a precursor in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and improve existing ones.
Used in Agrochemical Industry:
5,5-Dimethylpiperidin-2-one is used as a precursor in the synthesis of agrochemicals to help create effective pesticides and other agricultural products.
Used in Polymer Industry:
5,5-Dimethylpiperidin-2-one is used as a stabilizer in polymers to enhance their durability and performance, making them more resistant to environmental factors.
Used in Chemical Production:
5,5-Dimethylpiperidin-2-one is used as an intermediate in the production of UV absorbers and antioxidants, which are essential for various applications, including cosmetics, plastics, and coatings, to protect against harmful UV radiation and oxidative stress.

Upstream product

• 20500-49-6 3,3-dimethylcyclopentanone 
• 946082-44-6 ethyl 4-cyano-4-methylpentanoate 

Downstream Products

• 483358-28-7 6-ethoxy-3,3-dimethyl-2,3-dihydro-pyridine 
• 179685-59-7 1-Aza-2-methoxy-5,5-dimethyl-1-cyclohexene 

Relevant academic research and scientific papers

METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Synthesis and biological evaluation of dihydropyridin-2(1H)-imines and 1,5,6,7-tetrahydro-2H-azepin-2-imines

The process of discovery and biological evaluation of α,β-unsaturated cyclic amidines, as selective inhibitors of inducible nitric oxide synthase (iNOS), is reported. Dihydropyridin-2(1H)-imines and 1,5,6,7-tetrahydro-2H-azepin-2-imines were synthesized a

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: Synthesis and biological evaluation of dihydropyridin-2-imines

Dihydropyridin-2-imines were synthesized and biologically evaluated both in vitro and in vivo using a nitric oxide inhibition assay. Compounds 1, 4, 5 and 7-11 exhibited potent activity in the inducible nitric oxide (iNOS) inhibition assay. Of these 5, 6,

Cyclic amidine analogs as inhibitors of nitric oxide synthase

Disclosed herein are compounds of Formula I STR1 and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula I are also usful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, mulitple sclerosis, Korsakoff's disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents and for preventing or reversing tolerance to opiates and diazepines.